Naglazyme IV infusion 5mg, containing Galsulfase (genetically recombined), is manufactured by BioMarin Pharmaceutical Japan. This injectable drug, with YJ code 3959414A1023 and standard 5mg x 5mL x 1 bottle, is an enzyme replacement therapy indicated for patients with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome).
Naglazyme IV infusion 5mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).